Compare CNF & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNF | RNTX |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.7M | 38.9M |
| IPO Year | 2018 | N/A |
| Metric | CNF | RNTX |
|---|---|---|
| Price | $5.98 | $1.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 10.5K | ★ 234.4K |
| Earning Date | 08-28-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,241,013.00 | N/A |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.36 | $1.04 |
| 52 Week High | $13.90 | $3.50 |
| Indicator | CNF | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 53.37 |
| Support Level | $5.60 | $1.34 |
| Resistance Level | $6.10 | $1.58 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 90.00 | 62.50 |
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.